- Home
- CAC vs PLRX Comparison
CAC vs PLRX Comparison
Compare CAC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | PLRX |
|---|---|---|
| Founded | 1875 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 93.3M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAC | PLRX |
|---|---|---|
| Price | $42.96 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $47.33 | $3.79 |
| AVG Volume (30 Days) | 78.6K | ★ 1.9M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $215,172,000.00 | N/A |
| Revenue This Year | $44.50 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $34.53 | $1.10 |
| 52 Week High | $46.80 | $13.71 |
Technical Indicators
Market Signals| Indicator | CAC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 42.72 |
| Support Level | $43.60 | $1.20 |
| Resistance Level | $46.80 | $1.27 |
| Average True Range (ATR) | 0.87 | 0.06 |
| MACD | -0.46 | 0.01 |
| Stochastic Oscillator | 9.75 | 42.86 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.